EP2411530A2 - Dosage d'acides nucléiques sur phase solide combinant une capture et une détection à haute affinité par hybridation spécifique - Google Patents

Dosage d'acides nucléiques sur phase solide combinant une capture et une détection à haute affinité par hybridation spécifique

Info

Publication number
EP2411530A2
EP2411530A2 EP07759429A EP07759429A EP2411530A2 EP 2411530 A2 EP2411530 A2 EP 2411530A2 EP 07759429 A EP07759429 A EP 07759429A EP 07759429 A EP07759429 A EP 07759429A EP 2411530 A2 EP2411530 A2 EP 2411530A2
Authority
EP
European Patent Office
Prior art keywords
hybridization
target
probes
specific
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07759429A
Other languages
German (de)
English (en)
Inventor
Jens Burmeister
Ingmar Dorn
Brian Warner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Technology Services GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Technology Services GmbH filed Critical Bayer Technology Services GmbH
Publication of EP2411530A2 publication Critical patent/EP2411530A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Definitions

  • This invention relates to methods for detection of nucleic acids on a solid phase with high affinity and high specificity. More particularly, the invention relates to methods combining high-affinity hybridization-based capturing with highly specific hybridization-based discrimination in solid phase based nucleic acid assays. This invention further relates to kits containing the reagents necessary for carrying out the disclosed assays.
  • the detection of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) is of importance in human or veterinary diagnostics, food control, environmental analysis, crop protection, biochemical/pharmacological research, or forensic medicine.
  • capture oligonucleotides are immobilized on a solid support.
  • the labeled or unlabeled nucleic acid target is specifically hybridized to the capture probes.
  • the hybridization event can be detected using e.g. optical, electrical, mechanical, magnetic etc. readout technology.
  • optical, electrical, mechanical, magnetic etc. readout technology e.g. optical, electrical, mechanical, magnetic etc. readout technology.
  • the high specificity of base pairing interactions between stands of nucleic acids is used in these methods to differentiate between different targets.
  • Using a solid phase enables facile multiplexing of nucleic acid hybridization assays by spatially separating different capture oligonucleotides having different sequences. A huge number of different supports e.g.
  • Chips planar surfaces
  • beads or gel matrices can be used as solid phases.
  • Methods for preparation of DNA oligonucleotide arrays are summarized e.g. in S.L. Beaucage, Curr. Med. Chem. 2001, 8, 1213-1244 or M. C. Pirrung, Angew. Chem. 2002, 114, 1326-1341).
  • Solid phase based nucleic acid hybridization assays are widely used e.g. for analysis of single nucleotide polymorphisms (SNPs), expression profiling or viral detection (for a summary see e.g. J. Wang, Nucl. Acids Res. 2000, 28, 3011-3016.
  • the present invention is directed to a method for combining high specificity with high sensitivity in order to enable nucleic acid analysis on a solid surface from biological sources without prior amplification.
  • WO95/16055 An example of a nucleic acid assay which employs multiple hybridization reactions for combination of affinity and specificity is given in WO95/16055.
  • capture probes are bound to a surface.
  • One or more capture extender molecules are employed, each containing a target specific binding sequence and a support binding sequence able to hybridize to the surface bound capture probes.
  • the capture extender sequences are used to bind the target to the support with high affinity.
  • For detection e.g. amplification multimers are hybridized to the target in order to amplifiy signals.
  • Different sequences can be discriminated by specific hybridization of capture extenders containing sequences specific to different target regions. In case of targets with closely related sequences (e.g. targets containing mutations like single nucleotide polymorphisms) this approach does not work for more than one capture extender, because the differences in thermodynamic stabilities and thus melting temperatures are too small for effective discrimination.
  • US 2004/0009506 Al describes a nucleic acid hybridization assay that enables highly sensitive target capturing by using an immobilized capture polymer.
  • the capture polymer consists of target-specific capture sequences that are either directly or indirectly bound to a solid support.
  • the captured nucleic acid sequences are detected by hybridization of label probes containing two or more units of label bound to the label probe.
  • the disclosed assay type does not provide methods for high sensitivity detection of closely related sequences, e.g. sequences differing by a single base.
  • a similar assay type, combining high sensitivity capturing with highly specific enzymatic discrimination is disclosed in WO 2004/020654 A2.
  • target-specific capture sequences that are bound to a solid support either directly or indirectly capture a target from solution with high affinity.
  • Closely related sequences e.g. sequences differing by a single base
  • enzymes that incorporate the label during e.g. ligation or extension reactions.
  • This highly sensitive assay type enables qualitative and quantitative detection of closely related sequences from genomic samples without target amplification, it relies on the discriminative power of enzymes.
  • the incorporation of enzymes into the assay workflow adds a process step, increases assay cost and makes integration into fully- automated devices complicated.
  • nucleic acid assay formats that make use of a hybridization reaction of a target probe to a capture probe immobilized on a solid phase suffer from either sensitivity or selectivity or require enzymatic steps. Therefore, problems occur if e.g. single nucleotide polymorphisms must be detected in samples without prior target amplification in a fast, simple and inexpensive way.
  • Methods and kits are provided for detecting nucleic acids with high sensitivity and high specificity on a solid support.
  • the methods combine high affinity capture using one or more target specific oligonucleotides with highly specific hybridization-based discrimination methods.
  • Preferred methods include the use of one or more capture extender molecules for capturing the target with high affinity, in combination with a set of two or more hybridization probes that are specific for a particular variant of the target (e.g. wild type or single base mutated target).
  • the different hybridization probes are encoded by a particular type (e.g. a specific color) of label.
  • Figure 1 Summary of the assay in a preferred embodiment.
  • a target (5) containing a single base mutation (8) is hybridized to mixtures of target-specific capture probes (1) that are immobilized on a solid support (6) with or without a spacer (7) and are complementary to sequences of the target (2).
  • Allelic discrimination is achieved by hybridization of probes that contain an allele-specific site (4) and are labeled with different labeling entities (3).
  • FIG. 2 Summary of the assay in a preferred embodiment.
  • a target (5) containing a single base mutation (8) is hybridized to a mixture of immobilized capture probes (1) and an allele-specific discrimination probe containing an allele- specific site (4) on a solid support (6) with or without a spacer (7).
  • the capture probes are hybridized to sequences on the target (2) outside the single base mutation.
  • the target (6) is labeled with labeling entities (3) that are directly or indirectly attached to the target.
  • the invention combines high-affinity oligonucleotide capture with highly specific hybridization-based discrimination on a solid support, preferably for the detection of single nucleotide polymorphisms in multiplex assays without prior amplification of genomic DNA.
  • the invention makes use of two or more target- specific capture probes that are directly or indirectly attached to a solid support.
  • the capture probes can be spotted as mixtures of different oligonucleotides and covalently or noncovalently attached to a support. Alternatively, they can be hybridized to universal capture sequences immobilized as arrays on planar substrates.
  • each target can be separately captured in defined spots on the surface. This enables a multiplex detection of e.g. different gene fragments of a gene of interest in different spots on the surface. If more than one capture sequence hybridizes to the same target, cooperative binding leads to a significant increase in sensitivity thereby enabling detection of targets directly from genomic DNA without prior amplification.
  • the capture probes are immobilized on a solid support.
  • a spacer can be introduced between the surface and the hybridizing sequence.
  • This spacer can be composed of units that are capable of hybridization such as nucleotides and nucleotide analogs.
  • the spacer can be composed of units that are not capable of hybridization such as a hydrocarbon chain.
  • the hydrocarbon chain can also contain atoms taken from the 5 th or 6 th group of the periodic system, preferably nitrogen, phosphorous, oxygen or sulfur.
  • the spacer can also be composed of both nucleotide and non nucleotide units.
  • the capture probes are covalently immobilized on the planar surface via their 3'- or 5'-termini without a spacer on a planar substrate that is coated with a polymeric layer.
  • the polymeric layer ensures effective hybridization of the capture probes to the target.
  • the capture probes are covalently immobilized on a planar surface via their 3'- or 5 '-termini with a short spacer containing 2-20 units capable of hybridization, particularly preferred 2-10 units capable of hybridization on a planar substrate that is coated with a polymeric layer.
  • a variant in which the capture probes are covalently immobilized on a planar surface via their 3'- or 5'-termini with a spacer containing 3-30 ethylene glycol units is particularly preferred.
  • spacer molecules that can be attached to the 5'-terminus of capture probes include the commercially available Spacer Phosphoramidite 9 (3 ethylene glycol units and one phosphate unit), 18 (6 ethylene glycol units and one phosphate unit) and C3 (propanol unit and phosphate unit) as well as the Spacer Cl 2 CE Phosphoramidite (dodecanol unit and phosphate unit) from Glen Research, Sterling, Virginia, USA.
  • the capture probes are covalently immobilized on a solid support via a 5'-terminal spacer that contains 3-10 nucleotide units and 3-30 ethylene glycol units).
  • capture extenders are provided for each target and are covalently or non-covalently immobilized on a planar substrate as mixtures resulting in an array of mixtures of immobilized capture probes wherein a particular target can be captured within a particular spot.
  • the capture probes comprise a sequence of 5-100 nucleotides, preferably 10-50 nucleotides that is complementary to a particular target.
  • the targets captured by mixtures of capture probes that are arrayed on a solid substrate, are labeled during hybridization of label probes.
  • These label probes can be chosen from the group of molecules capable of hybridization that are known to persons skilled in the art e.g. DNA, DNA analogs, LNA and PNA.
  • the length and sequence of the label probes depend on the target to be detected.
  • mutations e.g. single nucleotide polymorphisms and deletions
  • targets are detected by differential hybridization of allele-specific hybridization probes.
  • targets are captured on an array of immobilized mixtures of capture probes, whereupon both alleles of a gene fragment containing a single nucleotide polymorphism are captured within the same spot.
  • allele-specific label probes are hybridized to the targets.
  • the hybridization probes are encoded with different labels such that each allele corresponds to a particular type of label.
  • two allele-specific label probes per target each encoded by a specific label compete during hybridization to a particular sequence containing a mutation.
  • the disclosed invention combines two levels of multiplexing: spatially resolved immobilization of mixtures of capture probes that are specific for particular gene fragments and specific hybridization of label-encoded probes that can distinguish between different variants of a target.
  • different hybridization probes are encoded by different labels. Therefore, two or more types of labels are needed for one preferred embodiment. Labels or groups enabling labeling reactions can be e.g. fluorophors, nanoparticles, redox active moieties, antibodies, antibody fragments, biotin, aptamers, peptides, proteins, mono- or polysaccharides, nucleic acids, nucleic acid analogs, complexing agents, cyclodextrins, crown ethers, anticalins, receptors etc. In one particularly preferred embodiment two or more hybridization probes are encoded by two or more different fluorescent dyes that emit fluorescence of different wavelengths.
  • two or more hybridization probes are encoded by two or more different fluorescent nanoparticles that emit fluorescence of different wavelengths. If the invention is carried out with one type of label, the sample to be analyzed must be split into two separate hybridization reactions, carried out on two different arrays. In a particular embodiment of this invention, two different alleles of a set of targets are detected on two different arrays, whereupon the labeled probe specific for one allele competes with the unlabeled probe of the other allele for hybridization to the target.
  • An alternative embodiment of the invention that also uses one type of label makes use of immobilized mixtures of probes, each of the hybridizing to a specific target.
  • capture probes are immobilized within the spots, that are specific to a particular variant of a target, e.g. a particular allele.
  • each allele of a target binds to a specific spot only if both the target- specific capture probes and the allele-specific capture probes become hybridized to the target.
  • the target can be labeled prior, during or after hybridization to the array using a method known to a person skilled in the art. Examples for labeling reactions include, but are not limited to, incorporation of dyes during primer extension, hybridization of labeling probes or chemical attachment of dyes.
  • fragmentation can be performed using different methods known to a person skilled in the art. Examples for fragmentation methods include, but are not limited to, sonication, enzymatic digestion, chemical fragmentation e.g. using radicals (as described e.g. in Y. Zhang et al., Nucleic Acids Res. 2001, 29, 13, e66). Fragmentation allows for the detection of a small (i.e. 50-1000 bp) sequence stretch within a target gene on one spot of the array. Thus, close-by mutations can be detected on different gene fragments in different spots of an array.
  • readout methods can be used to assess the result of the assay.
  • readout methods include optical, electrical, mechanical or magnetic detection. More specifically, fluorophores can be detected using e.g. planar optical waveguides as disclosed in US 5959292, total reflection on interfaces as disclosed in DE 196 28 002 or using optical fibers as disclosed in US 4815843. Nanoparticle labels can be detected e.g. via optical methods or e.g. by direct electrical detection after autometallographic enhancement as disclosed in US patents US 4794089, US 5137827 and US 5284748.
  • the disclosed invention requires a solid phase which is used to immobilize the capture probes. Examples for solid phases include, but are not limited to, beads, planar surfaces, metallic particles and gel matrices.
  • HET samples were obtained from the Coriell Cell Repository (Coriell Institute, Camden, NJ, USA): NAl 1497 (containing the SNP G542X, heterozygote, sample 2) and NA 12585 (containing the SNP R1162X, heterozygote, sample 3).
  • VAR sample was also obtained from the Coriell Institute: NAl 1496 (G542X, variant, sample 4). 60 ⁇ g genomic DNA from each sample was dissolved in Tris-
  • the samples were cooled on ice and sonified using a Branson Sonifier B 12 (Branson Ultrasonics Corp., Danbury, CT, USA) equipped with a microtip (3mm diameter) under the conditions of power 3 and 50% duty cycle for a total of 10 min.
  • the sonicated samples were precipitated by addition of 20 ⁇ l aqueous 5M NaCl and 2 ⁇ l glycogen solution (20mg/ml in water) and ImI of ice cold ethanol. Samples were incubated for 30 min. at -2O 0 C. Subsequently, the solutions were centrifuged 15 min at 13000 g.
  • the supernatant was removed and 400 ⁇ l of 70% ethanol were added to the precipitate. Subsequently the samples were centrifuged for 5 min. at 13000 g. The supernatant was removed, the pellets were dried under vacuum and redissolved in 40 ⁇ l of distilled water.
  • biochips (Unaxis AG, Balzers, Liechtenstein) with outer dimensions of 2x1 cm were obtained.
  • the chips consisted of glass and an optical grating with 18 nm deepness etched into the glass. They were coated with a 155nm thick layer of Ta2O5.
  • the chips were cleaned by the following protocol: 10 min sonication in 65% HNO 3 , rinsing by pure distilled water, 10 min sonication in 30% hydrogen peroxide, rinsing by pure distilled water, 10 min sonication in pure distilled water.
  • the PWG- chips were coated with aminopropyltriethoxysilane (APTES, Sigma, Deisenhofen, Germany) using the following protocol: drying of the cleaned chips @80°C for 5min, preparation of 100 ml silanization solution (1% APTES in acetone/water (95:5 v/v)), submerging the warm chips in the silanization solution, incubation for 15 min. at room temperature, rinsing of the chips 5 times by acetone, drying of the chips at 110 0 C for 45 min.
  • APTES aminopropyltriethoxysilane
  • the silanized chips were incubated in a 100ml solution of 1OmM suberic acid bis(N-hydroxysuccinimideester) in dimethylsulfoxide (DMSO) and 50 ⁇ L triethylamine for one hour. Thereafter, the chips were rinsed two times by DMSO and once by distilled water and blown dry in a stream of nitrogen. Two different mixtures of capture probes were prepared: mix 1 consisted of the following capture probe sequences:
  • CE002 CTAATTTTCTATTTTTGGTAATAGGAC ATTTTT-NH2
  • CE004 CAAGAATTTCTTTAGCAAGGTGAATAATTTTT-NH2
  • CE02 AAATAACAACATTTTTGTTTITAAGAATTTTTT-NH2
  • CE05 TCTCAATAATCATAACTTTCGAGAGTTTTTTT-NH2
  • AIl ten sequences were obtained from Thermo Hybaid Corporation, UIm, Germany and were synthesized with a 3 '-terminal amine (3 '-amino modifier by Glen Research, Sterlington, VA, USA).
  • the oligonucleotides were mixed in equal amounts to give solutions of mix 1 and mix 2 with a final DNA concentration of 5xlO-5M in potassion phosphate buffer, pH 7,2. These solutions were placed in small droplets (0.4 nl) onto the chip surface using a Biochip Arrayer (Perkin Elmer, Germany), creating two arrays of 4x4 spots on each chip and incubated overnight in a humid chamber.
  • Chips were rinsed once by 1 M NaOH solution and six times by distilled water. Capping of unreacted amino groups on the surface was performed by reaction with a solution of 0,4 mg/ml bis-sulfo-succinimidyl-suberate (BS3, Pierce, Rockford, IL, USA) in 0,1 M potassium phosphate buffer, pH 7,2 overnight. Chips were washed three times with distilled water, dried in a stream of nitrogen and used thereafter.
  • BS3 bis-sulfo-succinimidyl-suberate
  • Hybridization of genomic DNA to arrays of mixed capture probes Hybridization chambers were mounted onto the four biochips, thereby creating eight discrete chambers with a volume of approximately 100 ⁇ l each.
  • Eight different Allele Specific Hybridization probes (ASH-probes) were obtained from Thermo Hybaid Corporation, UIm, Germany.
  • the ASH-probes comprised the following oligonucleotides:
  • each of the sonicated DNA samples was mixed with an equal volume of denaturing diluent (taken from the Versant 3.0 bDNA assay kit, Bayer HealthCare LLC, Tarrytown, NY, USA) and incubated for Ih at 65°C.
  • ASH probes Two different mixtures of ASH probes were prepared: A wild type probe mix containing fA, B, fC and D at 5xl0-5M concentration each in a 1 :1 solution of neutralization solution (taken from the Versant 3.0 bDNA assay kit, Bayer HealthCare LLC, Tarrytown, NY, USA) and HIV 3.0 lysis solution (taken from the Versant 3.0 bDNA assay kit, Bayer HealthCare LLC, Tarrytown, NY, USA) supplemented with 5x Denhardt's solution (Sigma, Deisenhofen, Germany).
  • the variant probe mix consisted of the ASH probes fB, A, fD and C with the same buffers and additives as above.
  • the DNA samples (40 ⁇ l each) were mixed with 40 ⁇ l of the ASH probe mixes to give a total volume of 80 ⁇ l.
  • Each DNA sample was prepared in two different reaction mixtures containing the two different sets of ASH probes.
  • the resulting solutions were pipetted into the eight different hybridization chambers, sealed tightly and were incubated overnight at 54°C.
  • the chips were read out on a fluorescence reader, type Minifluo IV (Bayer Technology Services, Leverkusen Germany). The reader enabled to couple laser light into the optical grating and image the fluorescence with a CCD camera. Fluorescent intensity of each spot on the array was quantified and the mean of fluorescence for all mix 1 and mix 2 spots was calculated. The results are summarized in the table below:
  • the ratio of mean fluorescence intensities for each sample was calculated by dividing the signal for the wild type probe mix by the signal for the variant probe mix for the respective type of spots (spots mix 1 and spots mix 2). The results are given in the table below, expressed as log (wild type RFU / variant RFU):

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes de détection d'acides nucléiques sur une phase solide avec une haute affinité et une haute spécificité. Plus particulièrement, l'invention concerne des méthodes destinées à combiner une capture à haute affinité basée sur l'hybridation avec une discrimination hautement spécifique basée sur l'hybridation dans des dosages d'acides nucléiques sur phase solide. L'invention concerne également des trousses contenant les réactifs nécessaires pour réaliser les dosages susmentionnés. La détection d'acide désoxyribonucléique (ADN) ou d'acide ribonucléique (ARN) est importante dans le diagnostic d'une affection chez l'homme ou l'animal, le contrôle des produits alimentaires, l'analyse environnementale, la protection des cultures, la recherche biochimique/pharmacologique ou la médecine légale.
EP07759429A 2006-04-26 2007-03-27 Dosage d'acides nucléiques sur phase solide combinant une capture et une détection à haute affinité par hybridation spécifique Withdrawn EP2411530A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74573206P 2006-04-26 2006-04-26
US81572006P 2006-06-22 2006-06-22
PCT/US2007/064981 WO2007127564A2 (fr) 2006-04-26 2007-03-27 Dosage d'acides nucléiques sur phase solide combinant une capture et une détection à haute affinité par hybridation spécifique

Publications (1)

Publication Number Publication Date
EP2411530A2 true EP2411530A2 (fr) 2012-02-01

Family

ID=38566915

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07759429A Withdrawn EP2411530A2 (fr) 2006-04-26 2007-03-27 Dosage d'acides nucléiques sur phase solide combinant une capture et une détection à haute affinité par hybridation spécifique

Country Status (2)

Country Link
EP (1) EP2411530A2 (fr)
WO (1) WO2007127564A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013000682B3 (de) * 2013-01-08 2013-10-31 Rainer Hintsche Verfahren zur Detektion von Molekülen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020654A2 (fr) * 2002-08-30 2004-03-11 Bayer Healthcare Llc Dosages d'acide nucleique en rapport avec une phase solide, combinant une haute affinite avec une haute specificite

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4815843A (en) 1985-05-29 1989-03-28 Oerlikon-Buhrle Holding Ag Optical sensor for selective detection of substances and/or for the detection of refractive index changes in gaseous, liquid, solid and porous samples
US5137827A (en) 1986-03-25 1992-08-11 Midwest Research Technologies, Inc. Diagnostic element for electrical detection of a binding reaction
US4794089A (en) 1986-03-25 1988-12-27 Midwest Research Microscopy, Inc. Method for electronic detection of a binding reaction
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
JP3645907B2 (ja) 1994-05-27 2005-05-11 ノバルティス アクチエンゲゼルシャフト 漸減励起された発光を検出する方法
DE19628002C1 (de) 1996-07-11 1997-12-18 Inst Chemo Biosensorik Vorrichtung und Verfahren zur Durchführung von Fluoreszenzimmunotests
EP1495139A4 (fr) 2002-03-29 2006-06-28 Genentech Inc Procedes et compositions de detection et quantification d'analytes d'acides nucleiques
DE10224824A1 (de) * 2002-06-05 2003-12-24 Eppendorf Ag Verfahren zur Analyse von Target-Nukleinsäuresequenzen
US7601493B2 (en) * 2002-07-26 2009-10-13 Nanogen, Inc. Methods and apparatus for screening and detecting multiple genetic mutations
US20070105100A1 (en) * 2003-04-28 2007-05-10 Canon Kabushiki Kaisha Process for assay of nucleic acids by competitive hybridization using a dna microarray
US20050123959A1 (en) * 2003-09-30 2005-06-09 Brett Williams Methods and kits for hybridizing multiple probe panels to nucleic acid samples

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020654A2 (fr) * 2002-08-30 2004-03-11 Bayer Healthcare Llc Dosages d'acide nucleique en rapport avec une phase solide, combinant une haute affinite avec une haute specificite

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2007127564A2 *

Also Published As

Publication number Publication date
WO2007127564A3 (fr) 2008-04-03
WO2007127564A2 (fr) 2007-11-08

Similar Documents

Publication Publication Date Title
US7217522B2 (en) Genetic analysis by sequence-specific sorting
EP1601791B1 (fr) Analyse de reseau d'adn aleatoire par hybridation
EP3360972B1 (fr) Procédés d'analyse de séquence d'acide nucléique à molécule unique
EP1692152B1 (fr) Ameliorations apportees a des reseaux polynuceotidiques
AU771073B2 (en) Methods of nucleic acid amplification and sequencing
US6268147B1 (en) Nucleic acid analysis using sequence-targeted tandem hybridization
EP1645640B1 (fr) Procédé pour la détection des translocations chromosomales
JP4499987B2 (ja) 非−標準塩基を使用する固体支持体アッセイ系及び方法
US20090312193A1 (en) Microarray hybridization assay methods
US20030148284A1 (en) Solid phase detection of nucleic acid molecules
EP1438416A2 (fr) Dosages destines aux modifications de la methylation de l'adn
WO2005111237A1 (fr) Detection de troubles chromosomiques
EP1723261A1 (fr) Detection d'un strp, tel que le syndrome de l'x fragile
WO2007057652A1 (fr) Methode d'enrichissement de cible
EP0988398A1 (fr) Ensembles d'acide nucleique
US20080076121A1 (en) Microarray nuclease protection assay
WO2011052586A1 (fr) Procédé de détection d'un acide nucléique cible
WO2007106802A2 (fr) Procédé d'amplification linéaire d'adn modifié au bisulfite
US20060105337A1 (en) Solid phase based nucleic acid assays combining high affinity and high specificity
WO2005001113A2 (fr) Procedes de detection de variations d'acides nucleiques
Wang et al. Single nucleotide polymorphism discrimination assisted by improved base stacking hybridization using oligonucleotide microarrays
US20120141986A1 (en) Multivalent substrate elements for detection of nucleic acid sequences
EP2411530A2 (fr) Dosage d'acides nucléiques sur phase solide combinant une capture et une détection à haute affinité par hybridation spécifique
US8313905B2 (en) Detection oligomer and method for controlling quality of biochip using detection oligomer
Pastinen Single nucleotide polymorphism genotyping using microarrays

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090819

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BURMEISTER, JENS

Inventor name: WARNER, BRIAN

Inventor name: DORN, INGMAR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BURMEISTER, JENS

Inventor name: WARNER, BRIAN

Inventor name: DORN, INGMAR

R17P Request for examination filed (corrected)

Effective date: 20090411

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

17Q First examination report despatched

Effective date: 20131007

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20140218